Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a medical technology company focused on peripheral nerve repair, regeneration, and restoration of function. The AXGN news feed on this page aggregates company announcements, earnings releases, regulatory updates, and other disclosures related to its nerve repair portfolio and corporate activities.
Recent Axogen news has highlighted revenue growth, gross margin trends, and updated financial guidance, as well as developments in reimbursement coverage for nerve repair procedures using allografts and synthetic conduits. Earnings releases and accompanying conference calls provide details on revenue by quarter, profitability metrics, cash and investment balances, and management’s commentary on market development and commercial execution across extremities, oral and maxillofacial, head and neck, and breast reconstruction markets.
Regulatory milestones are a key theme in AXGN news. The company has reported FDA acceptance and subsequent approval of its Biologics License Application for Avance (acellular nerve allograft-arwx), including information on the Prescription Drug User Fee Act (PDUFA) review timeline, accelerated approval indications, and anticipated commercial availability under the biologic framework. Updates on professional society position statements and clinical practice guidelines recognizing nerve allograft as a standard medical practice option for peripheral nerve defects also appear in company communications.
Investors and observers can also find notices about Axogen’s participation in healthcare and investor conferences, where management presents the company’s strategy and meets with institutional investors. By following AXGN news here, readers can monitor financial results, regulatory progress, reimbursement developments, and corporate events that shape Axogen’s peripheral nerve repair business over time.
Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerves, announced that CEO Karen Zaderej will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 1:00 p.m. ET. The event will be available for live streaming on Axogen’s Investors page, with a replay accessible for 90 days. Axogen specializes in technologies for nerve regeneration and repair, offering products like Avance® Nerve Graft and Axoguard Nerve Connector® to restore peripheral nerve function, crucial after injuries or surgeries affecting the nervous system.
Axogen, Inc. (NASDAQ: AXGN) has appointed John H. Johnson to its Board of Directors as of July 19, 2021. Johnson brings over 30 years of biopharma experience from senior roles at major companies including Johnson & Johnson and Eli Lilly. He will contribute to both the Governance, Nominating and Sustainability Committee and the Science and Technology Committee. CEO Karen Zaderej highlights Johnson's expertise in pipeline strategy and commercial execution as a significant asset for the company’s ongoing commitment to innovation in peripheral nerve repair.
Axogen, Inc. (NASDAQ: AXGN) announced it will report Q2 2021 financial results on August 4, 2021, after market close. Management will host a conference call at 4:30 p.m. ET. Interested investors can participate via phone or listen online through Axogen's website. The company specializes in surgical solutions for peripheral nerve repair, offering products like Avance Nerve Graft and Axoguard Nerve Connector. Axogen aims to improve patient outcomes following peripheral nerve injuries.
Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve damage, announced presentations by CEO Karen Zaderej and CFO Peter Mariani at two investor conferences. They will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 11:30 a.m. ET, and the JMP Securities Life Sciences Conference on June 16, 2021, at 12:30 p.m. ET. Both events will be webcast live, with replays available on the Axogen Investors page for 90 days. Axogen focuses on the development and commercialization of technologies for peripheral nerve regeneration.
Axogen, a leader in surgical solutions for peripheral nerve repair, announced that Peter J. Mariani, CFO, will present at the Canaccord Genuity Musculoskeletal Conference on May 20, 2021, at 11:00 a.m. ET. The presentation will be accessible via live webcast on the company’s investor page. Axogen specializes in technologies that aid in the regeneration and repair of peripheral nerves, aiming to restore nerve function and quality of life for patients affected by nerve damage. Its product portfolio includes several innovative solutions such as Avance® Nerve Graft and Axoguard series.
Axogen, Inc. (NASDAQ: AXGN) reported a 28% increase in net revenue for Q1 2021, totaling $31.0 million compared to $24.3 million in Q1 2020. The gross margin improved to 83.3% from 80.1% year-over-year. Despite a net loss of $6.7 million or $0.16 per share, this was an improvement over the previous year’s loss of $8.2 million. The company ended Q1 2021 with $97.2 million in cash and investments. Axogen anticipates full-year 2021 revenue to be between $133 million and $136 million.
Axogen, Inc. (NASDAQ: AXGN) will announce its first quarter 2021 financial results on May 5, 2021, after market close. The company's management will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Interested investors can participate via phone or listen live on Axogen's website. The company focuses on developing innovative surgical solutions for peripheral nerve repair, including products like Avance® Nerve Graft and Axoguard Nerve Connector®. These offerings aim to restore nerve function and improve patient quality of life.
Axogen, Inc. (NASDAQ: AXGN) announced the promotion of Peter J. Mariani to Executive Vice President and Chief Financial Officer. Mariani, who has been with Axogen as CFO since 2016, has significantly enhanced the company’s capital structure and operational processes. In this new role, he will also oversee the Quality Assurance team. The company focuses on innovative solutions for peripheral nerve injuries, offering a comprehensive portfolio of products aimed at improving patient outcomes.
Axogen, Inc. (NASDAQ: AXGN) reported a 15% increase in fourth-quarter 2020 net revenue, totaling $32.5 million, up from $28.2 million in Q4 2019. Gross margin improved to 83.2%, while the net loss shrank to $6.0 million, representing a loss of $0.15 per share. Full-year revenue reached $112.3 million, a 5% rise compared to 2019, with a net loss of $23.8 million. Active accounts increased by 12% to 893, signaling growth in customer engagement. The company ended 2020 with $110.8 million in cash and equivalents, demonstrating financial stability amidst pandemic challenges.
Axogen, Inc. (AXGN) announced the completion of pilot phase analysis for its REPOSE clinical study, revealing significant pain reduction for subjects with chronic neuropathic pain. Results showed a mean pain decrease of 69 points at 3 months and 80 points at 12 months on a 100-point scale (p0.0001). Patients also reported improvements in fatigue, physical function, and sleep disturbances. Enrollment for the comparative phase of the study is expected to complete by Q1 2022. This study aims to evaluate the effectiveness of Axoguard Nerve Cap compared to standard neurectomy treatments.